GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Short Percentage of Float

Ardelyx (FRA:41X) Short Percentage of Float


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ardelyx's Short Percentage of Float

For the Biotechnology subindustry, Ardelyx's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Ardelyx's Short Percentage of Float falls into.


;
;

Ardelyx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Short Percentage of Float
Comparable Companies
DYN OCUL CLDX LQDA ADPT SPRY IOVA SNDX INVA AUPH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ARDX:USA 41X:Germany
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Website
https://www.ardelyx.com
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines